Data from recent researches has revealed users taking Acomplia medication have "an approximate doubling of the risk of" developing psychiatric disorders, and 10 consumers among 40,000 on the medicine committed suicide between June and July, compared to one suicide among those taking the placebo.Sanofi-Aventis, developer of Acomplia medication, temporarily suspended sales of Acomplia medicine following the announcement and told it would "immediately" start talks to have sales suspended in countries in Latin America, Asia and Africa where the dietary supplement also is available.
"More than 800,000 users have been treated with Acomplia supplement world-wide to date," Sanofi told in a statement. The company told that it had been monitoring "real-life use of the medication" and contended that the experience of consumers to date was "consistent with the one observed during the clinical development."
The European Medicines Agency told healthcare providers "should not issue any prescriptions for Acomplia medicine and should review the treatment of consumers currently taking the drug. Users who are currently taking Acomplia dietary supplement should consult their healthcare provider or pharmacist at a convenient time to discuss their treatment."
Sanofi told it believes Acomplia dietary medication will remain an important therapeutic answer to a highly prevalent and increasing unmet medical need, told it intended to continue the ongoing clinical research program.
No comments:
Post a Comment